Drug Pricing

White House says Trump's drug pricing deals could save $529 billion

White House economists estimate that President Donald Trump's deals with pharmaceutical companies to drop some of their US prescription drug prices to what they charge in other countries could save USD 529 billion over the next 10 years. The analysis obtained by The Associated Press includes the first economy-wide projections behind a policy at the core of Trump's pitch to voters going into November's midterm elections for control of the House and Senate. Democratic lawmakers have been doubtful about the savings claimed by Trump and these new numbers are likely to trigger additional questions about the data. Cost-of-living issues are at the forefront of voters' concerns and higher energy prices tied to the Iran war have deepened the public's anxiety. Trump has tried in part to address affordability concerns by focusing on his efforts to cut deals with companies so that the cost of prescription drugs in the US would no longer be dramatically higher than in other affluent nations. "

'Worst in Europe': Eli Lilly CEO slams UK drug prices, warns of fewer drugs

Eli Lilly CEO Dave Ricks slammed the UK's strict drug pricing rules, warning that the country risks losing new medicines and investment unless changes are made to its rebate scheme

NPPA revises ceiling prices of 923 scheduled drug formulations from April 1

The formulations in the new revised rate list include essential drugs such as painkillers, antivirals, antibiotics, antimalarials, and drugs for type 2 diabetes

Divi's Labs reports 49.2% loss in Q1 on back of drug pricing pressures

The company reported a consolidated profit of Rs 35,600 crore ($42.9 million) for the first quarter ended June 30, compared to Rs 702 crore a year ago

Govt, industry meet to focus on trade margin rationalisation of drugs

The Centre has been mulling on rationalizing drug trade margins for a while now for widely used medicines in an effort to bring down prices

Price war rages as pharma firms despatch Covid-19 antiviral pill

Competitive pricing among firms keeps rates at Rs 1,400-2,490 for full treatment

Near-term hiccups to have limited impact on Abbott India's growth: Experts

Despite the muted result and near term worries, the multinational drug major, India's second largest by market share is expected to post strong growth led by power brands and new launches

A cut that heals?

Price caps on drugs should be weighed carefully

Soon, drug makers will have to declare medicine cost price, MRP on labels

Pharma companies feat the move might hit their pricing strategies and put local firms in a disadvantageous position

Fixing drug prices: Regulator issues ultimatum to firms, seeks price data

For around 140 medicines in the list of essential medicines, the NPPA does not have market data

About 200 more drugs under price control

Earlier govt added 106 and removed 70 medicines from earlier one of 2011 expanding the list to 376 from 348